Manufacturing at Amgen

Below are the available bulk discount rates for each individual item when you purchase a certain amount

Register as a Premium Educator at, plan a course, and save your students up to 50% with your academic discount.

Publication Date:
February 01, 2021

Harvard School

Pharmaceutical industry

This case discusses efforts made by biotechnology (biotech) company Amgen to introduce technologies into its manufacturing processes. Doing so is complicated by the fact that the process for manufacturing biologics-or therapeutics made from living cells-is subject to unforeseen variability and thus requires a highly controlled environment. Mistakes are costly, given that the manufacturing process takes several weeks from start to finish. Set in early 2020, the case asks students to evaluate two opportunities facing case protagonists Myra Coufal and Chris Garvin. The first involves working with a new team to build a standard multivariate model for a fairly new commercial product with limited production data. The second involves building a predictive machine learning model to automate one step of the manufacturing process for a top-selling product that generates sizable margins. The case includes a supplemental problem set that provides students the opportunity to analyze data and make an informed choice between the two opportunities.

Copyright © 2021 Harvard School Publishing. All rights reserved. Harvard Publishing is an affiliate of Harvard Business School.

Digital Manufacturing at Amgen

& References of Digital Manufacturing at Amgen|A&C Accounting And Tax Services

Leave a Reply